SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.52 CNY | +2.31% |
|
+1.77% | +2.08% |
| Sales 2022 | 5.09B 704M 58.7B | Sales 2023 | 5.7B 787M 65.68B | Capitalization | 15.17B 2.1B 175B |
|---|---|---|---|---|---|
| Net income 2022 | 867M 120M 9.99B | Net income 2023 | 1.12B 155M 12.89B | EV / Sales 2022 | 1.97 x |
| Net cash position 2022 | 3.41B 471M 39.31B | Net cash position 2023 | 3.58B 494M 41.2B | EV / Sales 2023 | 2.03 x |
| P/E ratio 2022 |
15.7
x | P/E ratio 2023 |
13.5
x | Employees | 5,278 |
| Yield 2022 |
4.31% | Yield 2023 |
-
| Free-Float | 42.86% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.31% | ||
| 1 week | +1.77% | ||
| 1 month | +5.20% | ||
| 3 months | +16.88% | ||
| 6 months | +11.15% | ||
| Current year | +2.08% |
1 week
25.55
27.00
1 month
24.8827.65
Current year
21.5628.50
1 year
20.5430.32
3 years
12.8331.48
5 years
12.2931.48
10 years
10.9638.13
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Guan
CEO | Chief Executive Officer | 42 | 01/02/01 |
Chun Hong Wu
DFI | Director of Finance/CFO | 47 | - |
Fen Lan
CHM | Chairman | 46 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Chao Lin
BRD | Director/Board Member | 70 | 26/17/26 |
Jing Shang Ren
BRD | Director/Board Member | 62 | 20/11/20 |
Yi Guan
CEO | Chief Executive Officer | 42 | 01/02/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 4 M€ | -2.96% | ||
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 26.52 | +2.31% | 12,737,550 |
| 29/24/29 | 25.92 | -0.54% | 14,548,480 |
| 26/24/26 | 26.06 | -5.24% | 30,949,180 |
| 25/24/25 | 27.5 | +1.29% | 7,438,605 |
End-of-day quote Shenzhen S.E., April 30, 2024
More quotes
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs, chemical drugs, biopharmaceuticals and health products. The Company provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Companyâs main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
30/05/2024
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.08% | 2.14B | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- 002737 Stock
